---
---

# 21 U.S.C., USLM ref /us/usc/t21/s360bbb–8a

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–8.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–8b.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360bbb%E2%80%938a)

## § 360bbb–8a. Optimizing global clinical trials

    (a) __In general__ 

    The Secretary shall—

        (1) work with other regulatory authorities of similar standing, medical research companies, and international organizations to foster and encourage uniform, scientifically driven clinical trial standards with respect to medical products around the world; and

        (2)

         enhance the commitment to provide consistent parallel scientific advice to manufacturers seeking simultaneous global development of new medical products in order to—

            (A) enhance medical product development;

            (B) facilitate the use of foreign data; and

            (C) minimize the need to conduct duplicative clinical studies, preclinical studies, or nonclinical studies.

    (b) __Medical product__ 

        In this section, the term “medical product” means a drug, as defined in subsection (g) of [section 321 of this title][/us/usc/t21/s321], a device, as defined in subsection (h) of such section, or a biological product, as defined in [section 262(i) of title 42][/us/usc/t42/s262/i].

    (c) __Savings clause__ 

        Nothing in this section shall alter the criteria for evaluating the safety or effectiveness of a medical product under this chapter.

([June 25, 1938, ch. 675, § 569A][/us/act/1938-06-25/ch675/s569A], as added [Pub. L. 112–144, title XI, § 1123][/us/pl/112/144/s1123], July 9, 2012, [126 Stat. 1113][/us/stat/126/1113].)

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–8.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–8b.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360bbb%E2%80%938a)

----------
----------

[/us/usc/t21/s321]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs321
[/us/usc/t42/s262/i]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262%2Fi
[/us/act/1938-06-25/ch675/s569A]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs569A
[/us/pl/112/144/s1123]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs1123
[/us/stat/126/1113]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1113


